autoimmune

Bio & Pharma Celltrion to sell autoimmune drug Stelara biosimilar at Costco in US

South Korea’s leading biosimilar drug developer Celltrion Inc. said on Monday it is set to sell Steqeyma, a biosimilar to autoimmune disease t...

Bio & Pharma Celltrion wins EU approval for autoimmune disease treatment Avtozma

Celltrion Inc.’s Avtozma, a biosimilar to Roche’s autoimmune disease treatment Actemra, has won approval from the European Commission, f...

Bio & Pharma Celltrion obtains approval of Steqeyma from FDA

South Korea's Celltrion Inc. said on Wednesday it received new drug submission (NDS) approval from the Food and Drug Administration (FDA) for Steq...

Bio & Pharma Celltrion releases Steqeyma in Europe

South Korea's Celltrion Inc. said on Monday it released Steqeyma (ustekinumab) in Europe, the biosimilar of autoimmune disease treatment Stelara.T...

Bio & Pharma Celltrion's Zymfentra gets 90% distribution channel in US

South Korean biosimilar maker Celltrion Inc. said on Monday its subcutaneous injection formulation for autoimmune diseases, Zymfentra (infliximab), ...

Bio & Pharma IMBiologics transfers autoimmune disease drug tech to Huadong Pharma

South Korea's antibody-based biotech company IMBiologics announced on Friday that it signed a contract to transfer the technology of its autoimmune ...

Bio & Pharma Costco sells Celltrion's Yuflyma Low WAC in US

South Korea's Celltrion Inc. announced on Tuesday that its autoimmune disease treatment Yuflyma (Low WAC, active ingredient adalimumab) is now avail...

Bio & Pharma Celltrion gets approval of Steqeyma in Canada

South Korea’s Celltrion Inc., received new drug submission (NDS) approval from Health Canada for Steqeyma, a biosimilar of the autoimmune dise...

Bio & Pharma Celltrion to supply Remsima, Herzuma to Peru

South Korea's Celltrion Inc. announced on Thursday that it secured a contract to supply its biosimilars for autoimmune disease treatment and antican...

Bio & Pharma Samsung Bioepis gets OK to sell Stelara biosimilar in Europe

South Korea's Samsung Bioepis has received approval from the European Commission to sell Pyzchiva, a biosimilar of the autoimmune disease Stelara.&n...

Bio & Pharma Celltrion releases Remsima SC in Denmark

South Korea's Celltrion Inc. announced on Thursday that it released its autoimmune disease treatment Remsima SC (infliximab) in Denmark. Remsima SC ...

Bio & Pharma Celltrion'a autoimmune disease drug Zymfentra makes US debut

South Korean biopharmaceutical giant Celltrion Inc. said on March 17 that it has launched its new autoimmune disease treatment Zymfentra in the US m...

Bio & Pharma Celltrion ships initial supply of Zymfentra to US

South Korea's Celltrion Inc. announced on Wednesday that it shipped the first supply of its subcutaneous injection type of the autoimmune disease tr...

Bio & Pharma Samsung Bioepis to supply Hadlima to US government

South Korea’s Samsung Bioepis and the US-based Organon, the local partner company of Samsung group's biopharmaceutical research and developmen...

Bio & Pharma Celltrion to supply Remsima SC, Yuflyma to Norway

South Korea's Celltrion Inc. announced on Wednesday that it will supply its autoimmune disease treatments Remsima SC (infliximab) and Yuflyma, the...

Bio & Pharma Celltrion gets FDA approval for Remsima SC

South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...

Bio & Pharma Celltrion Healthcare wins Remsima order in France, Italy

South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...

Bio & Pharma Samsung Bioepis to cooperate with Swiss firm Sandoz

Samsung Bioepis Co., a biopharmaceutical research and development unit under South Korea's Samsung Group, announced on Monday that it signed a partn...

Bio & Pharma Handok to import treatment for rare autoimmune disorder

South Korean pharmaceutical company Handok Inc. on Wednesday said it signed a deal with Dutch immunology specialist Argenx to sell the latter's Vyvg...

Bio & Pharma Celltrion applies for approval in US for eye treatment biosimilar

South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...

Bio & Pharma Celltrion gets FDA approval for Humira biosimilar CT-P17

South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has obtained product approval from the US Food and Drug Adminis...

Bio & Pharma Daewoong to transfer techs for autoimmune disease to US pharma

South Korea's Daewoong Pharmaceutical announced on Friday that it has signed a technology export contract for the clinical development and commercia...

Bio & Pharma Celltrion Healthcare enters top 10 in hospital prescriptions in Turkey

South Korean biopharmaceutical company Celltrion Healthcare Co. on Thursday said it ranked in the top 10 out of 400 companies last year on the Turki...

Bio & Pharma Daewoong Pharma, UK firm to jointly develop autoimmune disease drug

South Korean drugmaker Daewoong Pharmaceutical Co. said on Tuesday that it has signed a cooperation agreement with Sygnature Discovery, a British ne...

Bio & Pharma Celltrion applies for EMA approval of smaller dose formulation of Yuflyma

Celltrion Inc. announced on Monday it applied to the European Medicines Agency (EMA) for approval of a 20 mg/0.2 mL formulation of Yuflyma, a biosim...

Bio & Pharma Celltrion develops oral antibody drug with US bio company

South Korea's biopharmaceutical company Celltrion Inc. on Monday said it signed an R&D contract with US-based Rani Therapeutics on RT-111, an or...

Bio & Pharma Celltrion applies for FDA approval for Remsima SC

Celltrion Ltd. said on Friday it had applied the previous day for permission from the US Food and Drug Administration (FDA) for Remsima SC, an autoi...

Bio Celltrion to co-develop pill-type autoimmune disease drug with UK startup

Biosimilar maker Celltrion Inc. has agreed to develop a tablet-type treatment for autoimmune diseases jointly with the UK biotech startup Intract Phar...